AACOCF3 (CAS 149301-79-1)
See product citations (10)
QUICK LINKS
AACOCF3 is an analogue of arachidonic acid in which the carboxyl group is replaced by a trifluoromethylketone. This compound is found to be a slow-binding inhibitor of cytosolic human phospholipase A2 (cPLA2). Mechanistic studies suggest that AACOCF3 inhibits cPLA2 by direct binding to the enzyme. cPLA2 takes part in eicosanoid biosynthesis and in cellular generation of free arachidonic acid (AA sc-200770) therefore AACOCF3 suppresses AA release. Additionally, this agent inhibits production of two major metabolites of AA produced by platelets, 12-hydroxyeigosatetraenoic acid and thromboxane B2 (TXB2 sc-201452). In other studies where cultured neuroblastoma cells were used, AACOCF3 was used as a ligand for a specific brain receptor therefore causing inhibition of anandamide (sc-205592) hydrolysis. AACOCF3 also inhibits fatty acid amide hydrolase (FAAH 100% at 7.5 µM). AACOCF3 is an inhibitor of group VI iPLA2.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
AACOCF3 (CAS 149301-79-1) References
- The inhibitor of phospholipase-A2, AACOCF3, stimulates steroid secretion by dispersed human and rat adrenocortical cells. | Andreis, PG., et al. 1999. Life Sci. 64: 1287-94. PMID: 10227584
- Involvement of cPLA2 inhibition in dexamethasone-induced thymocyte apoptosis. | Cinque, B., et al. 2008. Int J Immunopathol Pharmacol. 21: 539-51. PMID: 18831921
- Brain-derived neurotrophic factor stimulates production of prostacyclin in cerebral arteries. | Santhanam, AV., et al. 2010. Stroke. 41: 350-6. PMID: 20019327
- Inhibition of PLA2G4A Reduces the Expression of Lung Cancer-Related Cytokines. | Zhang, W., et al. 2018. DNA Cell Biol.. PMID: 30328712
- PLA2G4A/cPLA2-mediated lysosomal membrane damage leads to inhibition of autophagy and neurodegeneration after brain trauma. | Sarkar, C., et al. 2020. Autophagy. 16: 466-485. PMID: 31238788
- cPLA2 blockade attenuates S100A7-mediated breast tumorigenicity by inhibiting the immunosuppressive tumor microenvironment. | Mishra, S., et al. 2022. J Exp Clin Cancer Res. 41: 54. PMID: 35135586
- TCA-phospholipid-glycolysis targeted triple therapy effectively suppresses ATP production and tumor growth in glioblastoma. | Yang, S., et al. 2022. Theranostics. 12: 7032-7050. PMID: 36276638
- Identification of immune microenvironment subtypes and signature genes for Alzheimer's disease diagnosis and risk prediction based on explainable machine learning. | Lai, Y., et al. 2022. Front Immunol. 13: 1046410. PMID: 36569892
- Slow- and tight-binding inhibitors of the 85-kDa human phospholipase A2. | Street, IP., et al. 1993. Biochemistry. 32: 5935-40. PMID: 8018213
- Inhibitors of arachidonoyl ethanolamide hydrolysis. | Koutek, B., et al. 1994. J Biol Chem. 269: 22937-40. PMID: 8083191
- Arachidonyl trifluoromethyl ketone, a potent inhibitor of 85-kDa phospholipase A2, blocks production of arachidonate and 12-hydroxyeicosatetraenoic acid by calcium ionophore-challenged platelets. | Riendeau, D., et al. 1994. J Biol Chem. 269: 15619-24. PMID: 8195210
- Tight binding inhibitors of 85-kDa phospholipase A2 but not 14-kDa phospholipase A2 inhibit release of free arachidonate in thrombin-stimulated human platelets. | Bartoli, F., et al. 1994. J Biol Chem. 269: 15625-30. PMID: 8195211
- A specific inhibitor of cytosolic phospholipase A2 activity, AACOCF3, inhibits glucose-induced insulin secretion from isolated rat islets. | Loweth, AC., et al. 1996. Biochem Biophys Res Commun. 218: 423-7. PMID: 8561771
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AACOCF3, 5 mg | sc-201412C | 5 mg | $90.00 | |||
AACOCF3, 10 mg | sc-201412 | 10 mg | $159.00 | |||
AACOCF3, 50 mg | sc-201412A | 50 mg | $486.00 |